Consistent defined threshold and equity in health

Shekoufeh Nikfar, Zaheer Ud Din Babar, Rassoul Dinarvand, Abbas Kebriaeezadeh, Mohammad Abdollahi

Research output: Contribution to journalEditorial

Abstract

In measuring health, economic evaluations, the threshold is an important concept. It signifies the value of health gain and a new intervention is considered satisfactory if its price falls below a certain threshold [1].

Results are usually reported in an incremental cost-effectiveness ratio (ICER). The ICER stands for the additional costs per additional health unit produced by one intervention in comparison to another. A common tool for measurement is the quality-adjusted life-year (QALY). QALY encompasses both length and quality of life, which is based on utility. Likewise, various organizations and governmental bodies such as the National Institute for Health and Clinical Excellence (NICE) in the UK, Swedish Pricing and Reimbursement Board, the Pharmaceutical Benefits Advisory Committee in Australia, Dutch Health Care Insurance Board (CVZ) in The Netherlands have adopted certain threshold values. This adoption of threshold optimizes the process of allocation of health care resources [2].

Reimbursement decisions and allocation of health care resources is evolving in developing nations. Though cost-effectiveness analysis is increasingly being used for reimbursement mechanisms in developing countries, however, there is no consistent defined threshold. Most developing countries have adopted one to three times of their local gross domestic product (GDP) per capita as a threshold. This is also recommended by the World Health Organization (WHO). However, it is argued that the range of 1 to 3 folds is a wide range and hence it is imperative to evaluate the exact QALY threshold especially with regards to public preferences
Original languageEnglish
Article number12
JournalDARU, Journal of Pharmaceutical Sciences
Volume23
Issue number1
DOIs
Publication statusPublished - 10 Feb 2015
Externally publishedYes

Fingerprint

Cost-Benefit Analysis
Quality-Adjusted Life Years
Developing Countries
Health Resources
Delivery of Health Care
Reimbursement Mechanisms
Health
Gross Domestic Product
Costs and Cost Analysis
National Institutes of Health (U.S.)
Advisory Committees
Health Insurance
Netherlands
Quality of Life
Organizations
Health Equity
Pharmaceutical Preparations

Cite this

Nikfar, Shekoufeh ; Babar, Zaheer Ud Din ; Dinarvand, Rassoul ; Kebriaeezadeh, Abbas ; Abdollahi, Mohammad. / Consistent defined threshold and equity in health. In: DARU, Journal of Pharmaceutical Sciences. 2015 ; Vol. 23, No. 1.
@article{2e47a57472d14fa2aad2fe2cf9d8f808,
title = "Consistent defined threshold and equity in health",
abstract = "In measuring health, economic evaluations, the threshold is an important concept. It signifies the value of health gain and a new intervention is considered satisfactory if its price falls below a certain threshold [1].Results are usually reported in an incremental cost-effectiveness ratio (ICER). The ICER stands for the additional costs per additional health unit produced by one intervention in comparison to another. A common tool for measurement is the quality-adjusted life-year (QALY). QALY encompasses both length and quality of life, which is based on utility. Likewise, various organizations and governmental bodies such as the National Institute for Health and Clinical Excellence (NICE) in the UK, Swedish Pricing and Reimbursement Board, the Pharmaceutical Benefits Advisory Committee in Australia, Dutch Health Care Insurance Board (CVZ) in The Netherlands have adopted certain threshold values. This adoption of threshold optimizes the process of allocation of health care resources [2].Reimbursement decisions and allocation of health care resources is evolving in developing nations. Though cost-effectiveness analysis is increasingly being used for reimbursement mechanisms in developing countries, however, there is no consistent defined threshold. Most developing countries have adopted one to three times of their local gross domestic product (GDP) per capita as a threshold. This is also recommended by the World Health Organization (WHO). However, it is argued that the range of 1 to 3 folds is a wide range and hence it is imperative to evaluate the exact QALY threshold especially with regards to public preferences",
author = "Shekoufeh Nikfar and Babar, {Zaheer Ud Din} and Rassoul Dinarvand and Abbas Kebriaeezadeh and Mohammad Abdollahi",
year = "2015",
month = "2",
day = "10",
doi = "10.1186/s40199-015-0097-6",
language = "English",
volume = "23",
journal = "DARU, Journal of Pharmaceutical Sciences",
issn = "1560-8115",
publisher = "Teheran University of Medical Sciences",
number = "1",

}

Consistent defined threshold and equity in health. / Nikfar, Shekoufeh; Babar, Zaheer Ud Din; Dinarvand, Rassoul; Kebriaeezadeh, Abbas; Abdollahi, Mohammad.

In: DARU, Journal of Pharmaceutical Sciences, Vol. 23, No. 1, 12, 10.02.2015.

Research output: Contribution to journalEditorial

TY - JOUR

T1 - Consistent defined threshold and equity in health

AU - Nikfar, Shekoufeh

AU - Babar, Zaheer Ud Din

AU - Dinarvand, Rassoul

AU - Kebriaeezadeh, Abbas

AU - Abdollahi, Mohammad

PY - 2015/2/10

Y1 - 2015/2/10

N2 - In measuring health, economic evaluations, the threshold is an important concept. It signifies the value of health gain and a new intervention is considered satisfactory if its price falls below a certain threshold [1].Results are usually reported in an incremental cost-effectiveness ratio (ICER). The ICER stands for the additional costs per additional health unit produced by one intervention in comparison to another. A common tool for measurement is the quality-adjusted life-year (QALY). QALY encompasses both length and quality of life, which is based on utility. Likewise, various organizations and governmental bodies such as the National Institute for Health and Clinical Excellence (NICE) in the UK, Swedish Pricing and Reimbursement Board, the Pharmaceutical Benefits Advisory Committee in Australia, Dutch Health Care Insurance Board (CVZ) in The Netherlands have adopted certain threshold values. This adoption of threshold optimizes the process of allocation of health care resources [2].Reimbursement decisions and allocation of health care resources is evolving in developing nations. Though cost-effectiveness analysis is increasingly being used for reimbursement mechanisms in developing countries, however, there is no consistent defined threshold. Most developing countries have adopted one to three times of their local gross domestic product (GDP) per capita as a threshold. This is also recommended by the World Health Organization (WHO). However, it is argued that the range of 1 to 3 folds is a wide range and hence it is imperative to evaluate the exact QALY threshold especially with regards to public preferences

AB - In measuring health, economic evaluations, the threshold is an important concept. It signifies the value of health gain and a new intervention is considered satisfactory if its price falls below a certain threshold [1].Results are usually reported in an incremental cost-effectiveness ratio (ICER). The ICER stands for the additional costs per additional health unit produced by one intervention in comparison to another. A common tool for measurement is the quality-adjusted life-year (QALY). QALY encompasses both length and quality of life, which is based on utility. Likewise, various organizations and governmental bodies such as the National Institute for Health and Clinical Excellence (NICE) in the UK, Swedish Pricing and Reimbursement Board, the Pharmaceutical Benefits Advisory Committee in Australia, Dutch Health Care Insurance Board (CVZ) in The Netherlands have adopted certain threshold values. This adoption of threshold optimizes the process of allocation of health care resources [2].Reimbursement decisions and allocation of health care resources is evolving in developing nations. Though cost-effectiveness analysis is increasingly being used for reimbursement mechanisms in developing countries, however, there is no consistent defined threshold. Most developing countries have adopted one to three times of their local gross domestic product (GDP) per capita as a threshold. This is also recommended by the World Health Organization (WHO). However, it is argued that the range of 1 to 3 folds is a wide range and hence it is imperative to evaluate the exact QALY threshold especially with regards to public preferences

UR - http://www.scopus.com/inward/record.url?scp=84924276643&partnerID=8YFLogxK

U2 - 10.1186/s40199-015-0097-6

DO - 10.1186/s40199-015-0097-6

M3 - Editorial

VL - 23

JO - DARU, Journal of Pharmaceutical Sciences

JF - DARU, Journal of Pharmaceutical Sciences

SN - 1560-8115

IS - 1

M1 - 12

ER -